Alantra advises Affidea on the acquisition of Uroviva Group, becoming one of the top outpatient healthcare providers in Switzerland

Mar 2025

Buy-side advisory

Frankfurt – Alantra has acted as financial advisor to Affidea Group, a leading pan-European provider of specialist healthcare services including cancer care, advanced diagnostic imaging and community-based polyclinics, on the acquisition of Uroviva Group, Switzerland’s foremost urology network, from German Equity Partners IV, a fund managed by independent German investment company ECM, and Uroviva Group’s founding physicians.

Through this acquisition, Affidea Switzerland almost doubles in size, from 17 to 33 centers and from 450 to 700 employees, positioning the company among the top five outpatient healthcare providers in the country. This acquisition complements Affidea’s out-of-hospital diagnostic services and opens significant synergies in pathology, diagnostic imaging and oncology. These complementary services allow Affidea to offer an integrated pathway in breast and prostate cancer care, delivering seamless and connected patient care experiences.

The Uroviva Group is a leading network of medical specialists, combining top-level expertise in urology, gynecology, and oncology. With 16 locations across Switzerland and approximately 250 employees, Uroviva provides comprehensive outpatient care as well as inpatient treatment where required. By combining their services, the Uroviva centers and Affidea’s existing network will create a unique model of integrated care, offering patients faster access to diagnostics, personalized treatment plans, and continuous monitoring.

Marc-Andre Christinat, CEO of Affidea Switzerland, said: “With Uroviva joining our network, we are not only doubling our footprint in the country but also creating a leading national platform for integrated oncology care. It is not just a strategic expansion, it’s a commitment to our patients, doctors and the communities we serve. We appreciated Alantra’s collaborative approach throughout the process, supporting a smooth and efficient transaction that sets the foundation for long-term value creation.”

Razvan Predica, Chief Commercial Officer for Affidea Group, added: “This transaction reflects our continued focus on high-impact growth opportunities that align with Affidea’s strategy of building integrated, specialist care platforms across Europe. Alantra’s deep sector knowledge, strong execution capabilities and strategic input were key points in delivering a successful outcome on this important acquisition for us”.

Christopher Jobst, Managing Director at Alantra, said: “We are pleased to have advised Affidea in this successful transaction. The partnership with Uroviva creates a highly complementary platform with a leading market position in Switzerland and we look forward to seeing what it achieves in its next phase of growth.”

André Hüneburg, Director at Alantra, added: “Our team provided senior M&A advisory throughout the entire process, leveraging our deep expertise of the DACH healthcare services industry to provide Affidea with unique access to the sellers, navigating the transaction towards a successful outcome for both parties.”

This transaction underscores Alantra’s expertise in the healthcare sector, building on the recent advisory of KIRKBI on its investment in AMBOSS, Oakley Capital on the strategic combination of Windstar Medical and Merz Lifecare, and Trill Impact on its partnership with TT medic Group.